New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 17, 2024 - AbbVie announced the FDA approval of Vyalev (foscarbidopa/ foslevodopa), for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD).
Download PDF
Return to publications
